4//SEC Filing
Sagent Pharmaceuticals, Inc. 4
Accession 0000899243-16-028308
CIK 0001369786operating
Filed
Aug 30, 8:00 PM ET
Accepted
Aug 31, 6:23 PM ET
Size
25.4 KB
Accession
0000899243-16-028308
Insider Transaction Report
Form 4
FLANAGAN ROBERT J
Director
Transactions
- Disposition to Issuer
Stock Option to Buy
2016-08-29$10.15/sh−5,103$51,795→ 0 totalExercise: $11.60Exp: 2020-12-02→ Common Stock (6,379 underlying) - Disposition from Tender
Common Stock
2016-08-29$21.75/sh−433,770$9,434,498→ 0 total(indirect: See Footnote) - Disposition to Issuer
Restricted Stock Units
2016-08-29$21.75/sh−691$15,029→ 0 total→ Common Stock (691 underlying) - Disposition from Tender
Common Stock
2016-08-29$21.75/sh−8,050$175,088→ 0 total - Disposition from Tender
Common Stock
2016-08-29$21.75/sh−2,000$43,500→ 0 total(indirect: See Footnote) - Gift
Common Stock
2016-08-16−4,150→ 8,050 total - Disposition to Issuer
Restricted Stock Units
2016-08-29$21.75/sh−1,860$40,455→ 0 total→ Common Stock (1,860 underlying) - Disposition to Issuer
Restricted Stock Units
2016-08-29$21.75/sh−8,556$186,093→ 0 total→ Common Stock (8,556 underlying) - Disposition to Issuer
Restricted Stock Units
2016-08-29$21.75/sh−760$16,530→ 0 total→ Common Stock (760 underlying) - Disposition to Issuer
Restricted Stock Units
2016-08-29$21.75/sh−1,381$30,037→ 0 total→ Common Stock (1,381 underlying)
Footnotes (11)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were disposed of in a cash tender offer by Shepard Vision, Inc. to acquire common stock of Sagent Pharmaceuticals, Inc. in exchange for $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Consideration").
- [F10]The restricted stock units provided for vesting in four equal annual installments beginning on February 21, 2014.
- [F11]Represents the disposition of options, which provided for vesting in four equal installments beginning December 2, 2011. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $10.15 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F2]The shares reported are held by Flanagan Family Limited Partnership. Mr. Flanagan is a managing member of E.O. Flanagan LLC, the general partner of Flanagan Family Limited Partnership.
- [F3]The shares reported are held of record by CNF Investments II, LLC. Voting and investment decisions with respect to all shares held by CNF Investments II, LLC are exercised by its managing member, Mr. Flanagan. Accordingly, Mr. Flanagan may be deemed the beneficial owner of such shares.
- [F4]Each restricted stock unit represents a contingent right to receive one share of SGNT common stock.
- [F5]The restricted stock units provided for vesting on February 22, 2017.
- [F6]Each restricted stock unit was disposed pursuant to the Merger Agreement whereby each such restricted stock unit was cancelled and converted into the right to receive the Consideration.
- [F7]The restricted stock units provided for vesting in four equal annual installments beginning on April 9, 2016.
- [F8]The restricted stock units provided for vesting in four equal annual installments beginning on February 25, 2016.
- [F9]The restricted stock units provided for vesting in four equal annual installments beginning on February 18, 2015.
Documents
Issuer
Sagent Pharmaceuticals, Inc.
CIK 0001369786
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001369786
Filing Metadata
- Form type
- 4
- Filed
- Aug 30, 8:00 PM ET
- Accepted
- Aug 31, 6:23 PM ET
- Size
- 25.4 KB